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A new generation of physicians and scientists should
obtain a copy of Endocrine Therapy of Breast Cancer.
The book is a welcome addition to one’s personal library
or for purchase by a departmental library. The style and
presentation are good with an excellent balance of clinical
research and basic science. Although it is not stated, the
prospective audience seems to be physicians-in-training,
scientists engaged in cancer research and PhD students
who need to learn about pioneering advances in targeted
cancer therapeutics.
The book is divided into 15 chapters with two major sec-
tions covering the use of endocrine therapy in clinical
practice and the biological aspects of endocrine therapy.
The two clinical editors, Daniel Hayes and John Robertson
open the first chapter with powerful statements: 1) “one of
the greatest success stories in the history of cancer treat-
ment has been the application of endocrine treatment for
breast cancer” and 2) “it is fair to say that endocrine
therapy can be considered the paradigm for molecular
medicine as a whole with a considerable two-way interac-
tion between the laboratory and the clinic.” The editors
have selected a distinguished medical oncologist, Gabriel
Hortobagyi, to write the Forward because he witnessed
the “quiet revolution” and saw how the knowledge about
the oestrogen receptor, which at that time was a potential
predictive test for endocrine ablative surgery, was trans-
formed to become a successful target for therapeutics.
It is important to have a book that states where we are and
where a future path will take us and the authors do a good
job with this work. Robert Nicholson is an excellent scien-
tific resource and provides an outstanding perspective to
the current and future directions in endocrine research.
Kathleen Pritchard, another author whose experience
reaches back to the genesis of targeted endocrine
therapy, writes an encyclopedic chapter on ovarian abla-
tion. For a revised edition (and there should be revised
editions in this pharmaceutically important area) I would
like to see a separate chapter on a balanced argument
about the endocrinology and efficacy of combination
chemotherapy versus complete endocrine blockade in
oestrogen receptor positive premenopausal patients.
Perhaps a combined chapter from opposing camps would
be fun!
The editors, for completeness, state the laboratory and
clinical case for antiprogestins as rational therapy in breast
cancer. A case for a role of progesterone or progestins in
carcinogenesis can be made both in the laboratory and
clinic but the development of an antiprogestin as a tar-
geted breast cancer drug has “lost the plot”. The
response rate with antiprogestins has been extremely low
and the concern I have is that at the 100 mg daily doses
they also have oestrogenic actions [1]. Could the results
with antiprogestins, at enormous doses, be a variation on
“high dose” oestrogen therapy in breast cancer? This is
not an unreasonable suggestion as we go back to the
future and again consider oestrogen therapy after exhaus-
tive antihormone treatment as stated in Chapter 4. There
needs to be a rethink in subsequent editions about the
need for antiprogestin chapters. Nevertheless, there is
clearly a need to address the shortcomings of the concept
today.
Finally, as a molecular pharmacologist, my evaluation of
accuracy is often drawn to the formulae. The structure is
the life or death of a targeted molecule. Unfortunately, the
editors need to encourage the publisher to transpose for-
mulae correctly, as incorrect structures can mislead in a
reference work. Page 48 is a case in point with many for-
mulae incorrectly copied (5 out of 10) and one investiga-
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tional compound, SR16234, is not referenced in the text.
This is not the only problem as the structure of anastrozole
is incorrect on page 236.
Despite these minor shortcomings, the editors and
authors provide a new generation with an excellent state-
of-the-art book. The work truly reflects how much has
been achieved in endocrine therapy in thirty years. The key
to the successful advance with medicines targeted to the
oestrogen receptor was the resurrection of the compound
ICI 46,474, as tamoxifen, after it was abandoned in 1972.
Although the story of the development of tamoxifen is not
mentioned in the book it is documented elsewhere [2].
Although my clinical colleagues in the book trace the story
back to George Beatson and a response in a single
patient in 1896, I think that success for molecular target-
ing in cancer in modern times can be viewed quite simply.
When asked how contraceptives worked, Gregory Pincus,
the father of the oral contraceptive, replied, “no ovulation,
no egg, no baby.” By analogy, the evolution of the
Endocrine Therapy of Breast Cancer could be summa-
rized as – no target (oestrogen receptor), no drug (tamox-
ifen), no story.
Competing interests
None declared.
References
1. Jeng MH, Langan-Fahey SM,Jordan VC: Estrogenic actions of
RU486 in hormone-responsive MCF-7 human breast cancer
cells. Endocrinology 1993, 132:2622-2630.
2. Jordan VC: Tamoxifen: a most unlikely pioneering medicine.
Nature Reviews Drug Discovery 2003, 2:205-213.
Correspondence
Robert H Lurie, Comprehensive Cancer Center, Northwestern Univer-
sity Medical School, 303 East Chicago Avenue, Olson Pavilion, 8258
Chicago, IL 60611, USA. Tel: +1 312 908 4162; fax: +1 312 908
1372; e-mail: vcjordan@northwestern.edu